Activation of anti-sars-cov-2 human ctls by extracellular vesicles engineered with the n viral protein

HIGHLIGHTS

• who: Francesco Manfredi et al. from the National Center for Global Health, Istituto Superiore di Sanitu00e0, Viale Regina Elena, Rome, Italy have published the article: Activation of Anti-SARS-CoV-2 Human CTLs by Extracellular Vesicles Engineered with the N Viral Protein, in the Journal: Vaccines 2022, 1060 of /2022/
• what: The authors propose an innovative anti-SARS-CoV-2 immune strategy based on extracellular vesicles (EVs) inducing an anti-SARS-CoV-2 N CD8+ T cytotoxic lymphocyte (CTL) immune response. This achievement represents a mandatory step towards the upcoming experimentations in pre-clinical models . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.